SCHEMBL1719403

SCHEMBL1719403

COc1ccc(CNCCc2ccc(O)cc2)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.67
SLC2A1 P11166 1/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56
CA9 Q16790 1/20 0.56
CYP3A4 P08684 3/20 0.53
TSHR P16473 2/20 0.53
NFKB1 P19838 2/20 0.53
CYP1A2 P05177 1/20 0.53
ALOX15 P16050 1/20 0.53
ALOX12 P18054 1/20 0.53
LMNA P02545 3/20 0.52
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SLC22A1 O15245 1/20 0.52
ADRB2 P07550 1/20 0.52
CHRM2 P08172 1/20 0.52
ADRB1 P08588 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213077 1.00 BCHE (0.67) BCHESLC2A1CA12CA1CA2
SCHEMBL5069115 0.90 BCHE (0.76) BCHESLC2A1CA12CA1CA2
SCHEMBL8532510 0.88 ALOX15 (0.62) CYP3A4TSHRNFKB1CYP1A2ALOX15
SCHEMBL27182644 0.83 ALOX15 (0.57) CYP3A4TSHRNFKB1CYP1A2ALOX15
SCHEMBL30873035 0.83 ALOX15 (0.57) CYP3A4TSHRNFKB1CYP1A2ALOX15
SCHEMBL5355216 0.83 SMN1; SMN2 (0.62) BCHECA12CA1CA2CA4
SCHEMBL27183000 0.82 TUBB4A (0.70) CYP3A4TSHRNFKB1CYP1A2ALOX15
SCHEMBL30873175 0.82 TUBB4A (0.70) CYP3A4TSHRNFKB1CYP1A2ALOX15
SCHEMBL9073446 0.81 KDM4E (0.64) BCHECA12CA1CA2CA4
SCHEMBL30213072 0.81 ALOX15 (0.59) BCHESLC2A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2009015-B1 Process for the preparation of galantamine hydrobromide AUROBINDO PHARMA LTD (IN) 2012-01-11 EP disclosed
EP-2009015-A1 An improved process for the preparation of galantamine hydrobromide Aurobindo Pharma Limited (IN) 2008-12-31 EP disclosed
EP-2009015-A1 An improved process for the preparation of galantamine hydrobromide Aurobindo Pharma Limited (IN) 2008-12-31 EP disclosed
WO-2006072818-A2 PROCESS FOR PREPARATION OF GALANTHAMINE EMCURE PHARMACEUTICALS LIMITED (IN) 2006-07-13 WO disclosed
US-6407229-B1 ENZYME INHIBITOR SANOCHEMIA PHARMAZEUTIKA AG (AT) 2002-06-18 US disclosed
US-6369238-B1 ENZYME INHIBITORS USED IN THE TREATMENT OF ALZHEIMER'S DISEASE SANOCHEMIA PHARMAZEUTICA (AT) 2002-04-09 US disclosed
US-6043359-A REACTING A BENZALDEHYDE DERIVATIVE WITH A BENZENE ETHYLAMINE DERIVATIVE TO FORM A SCHIFF BASE, REDUCING THE SCHIFF BASE TO PRODUCE AN INTERMEDIATE, OXIDATIVELY CYCLYZATION, THEN STEREOSELECTIVE REDUCTION FORMS END PRODUCT SANOCHEMIA PHARMAZEUTICA AKTIENGESELLSCHAFT (AT) 2000-03-28 US disclosed
EP-0787115-B1 PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE SANOCHEMIA PHARMAZEUTIKA AG (AT) 2000-01-05 EP disclosed
EP-0787115-A1 PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO 3a,3,2-ef] 2]BENZAZEPINE Waldheim Pharmazeutika Gesellschaft m.b.H. (AT) 1997-08-06 EP disclosed
WO-1996012692-A1 PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE WALDHEIM PHARMAZEUTIKA GESELLSCHAFT M.B.H. (AT) 1996-05-02 WO disclosed